Search

Your search keyword '"A. Barletta"' showing total 296 results

Search Constraints

Start Over You searched for: Author "A. Barletta" Remove constraint Author: "A. Barletta" Journal european urology Remove constraint Journal: european urology
296 results on '"A. Barletta"'

Search Results

1. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

2. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study

3. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging–targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy

4. The impact of multiple lesions in prostate MRI – insights from the YAU prostate cancer group

5. PSA doubling time thresholds in predicting clinical recurrence after biochemical recurrence in surgically treated prostate cancer patients. The Impact of nodal status and adjuvant radiotherapy

6. Does the accuracy of PSA density change according to prostate volume? Assessing the diagnostic accuracy at the extreme values of prostate volume in a large single institution series

7. Assessing epigenetic features associated with lymph node metastases in prostate cancer

8. Optimizing detection and prediction of prostate cancer after positive MRI and negative biopsies

9. Age-dependent effect of early salvage radiotherapy for biochemical recurrence in prostate cancer patients treated with radical prostatectomy

10. The significant added value of concomitant systematic prostate biopsies in addition to targeted sampling in patients with previous negative biopsies. Implications for accurate staging predictions from a large multi-institutional series

11. PSMA radio-guided surgery to detect nodal metastases in prostate cancer patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection: Updated results of a planned interim analysis of a prospective phase 2 study

12. Prognostic significance of lymph node count in surgically treated patients with T2-4 stage non-metastatic adrenocortical carcinoma

13. The more you see the more you miss. PSMA PET/CT is still affected by a substantial risk of underestimation in prostate cancer patients undergoing radical prostatectomy

14. External validation of the available nomograms for the identification of candidates for a staging extended pelvic lymph node dissection at the time of radical prostatectomy in prostate cancer patients preoperatively staged with PSMA PET

15. Identifying the optimal definition of PSA response after metastasis directed therapy in men with oligo-recurrent prostate cancer detected at PSMA PET

16. Long-term oncological outcomes of surgically managed very high-risk prostate cancer patients according to the STAMPEDE trial definition: Implications for the selection of candidates for clinical trials

17. The effect of treatment dose intensification on other-cause mortality in clear-cell metastatic renal cell carcinoma patients

18. Validation of the EAU risk groups for radical prostatectomy prostate cancer patients who experienced biochemical recurrence restaged with PSMA PET imaging and development of a novel tool

19. The role of artificial intelligence for the detection of clinically significant prostate cancer at multiparametric magnetic resonance imaging

20. Optimizing the number of systematic cores during MRI target biopsy. Preliminary results from the prospective, paired-cohort SCOT Trial

21. Effect of Metastasis Directed Therapy (MDT) in men with PSMA PET detected recurrent prostate cancer according to time from primary treatment. Do men with late recurrences really benefit from MDT? Results from a large, single institution series

22. The importance of high volume providers in the diagnostic pathways of prostate cancer. Results from large, singe Institution series

23. Towards a tailored use of PSA density to decide when to avoid prostate biopsy in men with PIRADS 3 lesions according to the location of the index lesion at mp-MRI. Results of a large, multi-institutional series

24. Oncological outcomes of pN1 prostate cancer patients treated with radical prostatectomy: Does molecular imaging have a prognostic impact? Results of a large, multi-institutional series

25. How can we reduce the rates of false positive findings at mpMRI? The pivotal role of urologist expertise assessed in a large, single center series

26. Adjuvant or early salvage radiotherapy in node positive prostate cancer patients: Development of a novel risk score to identify the optimal candidate for early intensification approaches based on a large, multi-institutional series

29. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries

30. When is central histological review of prostate biopsy really needed to reduce the risk of misclassification of prostate cancer? The importance of patient risk stratification

31. Differences in survival of clear cell metastatic renal cell carcinoma patients according to partial vs. radical nephrectomy

32. Adenocarcinoma of the bladder: Assessment of survival benefit associated with radical cystectomy and comparison with urothelial bladder cancer

33. Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer

34. Tailoring the optimal use of androgen-deprivation therapy concomitant to post-operative radiotherapy among men with pN1 prostate cancer. Long-term results of a large, single Institution series

35. Can we predict the site of positive surgical margins based on the site of the index lesion at multiparametric mri? A topographic, single center study

38. Which men with cN1 prostate cancer at PSMA PET/CT represent the ideal candidate for radical prostatectomy? Development of a novel risk stratification tool for individualized approaches based on a large, multi-institutional series

41. A systematic review to evaluate Patient-Reported Outcomes Measures (PROMs) for metastatic prostate cancer according to the COSMIN methodology – A PIONEER wp2 project

42. Improving prediction of local stage by PSMA-PET: Development of a novel integrated tool for extracapsular extension and seminal vesicle invasion combining clinical and imaging features in localized prostate cancer

43. Identifying the optimal candidates for concomitant androgen-deprivation therapy among patients receiving metastasis-directed therapy for positive 68Ga-PSMA PET/CT for biochemical recurrent prostate cancer after radical prostatectomy

48. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study

50. The prognostic role of 68Ga-PSMA PET/CT and the impact of metastasis-directed therapy on cancer progression in men with biochemical recurrence from prostate cancer. Results from a large, single Institution series

Catalog

Books, media, physical & digital resources